IGF2BP2 and neoplasm: Targeting the LINRIS‐IGF2BP2 axis may provide therapeutic benefits in CRC, as evidenced by reduced tumor proliferation in both orthotopic and patient‐derived xenograft models upon LINRIS inhibition.[152]